Pontifax

Lutris Pharma is a biopharmaceutical company based in Tel Aviv-Yafo, Israel, founded in 2015. The company focuses on developing therapeutic drugs aimed at enhancing the effectiveness of anti-cancer therapies. Its lead product, LUT014, is a proprietary small molecule B-Raf inhibitor designed to facilitate the administration of epidermal growth factor receptor (EGFR) inhibitors. This innovative approach helps mitigate the common cutaneous side effects associated with EGFR treatments, thereby improving the overall quality of life for patients undergoing cancer therapy.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Raziel Health is a pharmaceutical company based in Rehovot, Israel, focused on developing innovative treatments for obesity and related fat disorders. The company's primary product, RZL-012, is a synthetic small molecule designed for injection into subcutaneous fat, where it induces fat cell death at the injection site, leading to a significant and long-lasting reduction in fat tissue. Raziel Health is actively conducting clinical trials to explore the efficacy of RZL-012 for various fat-related conditions, including Dercum's disease, as well as for aesthetic purposes. In addition to its pharmaceutical endeavors, Raziel Health aims to enhance healthcare accessibility by offering integrated technologies that promote timely clinical intervention and support individual patient wellness and disease management from the comfort of their homes.

Pi Therapeutics is a discovery-stage biopharmaceutical company aiming to develop a novel cancer drug. The company is financed by a syndicate of Takeda Pharmaceutical Company through its venture group Takeda Ventures Inc., Johnson & Johnson Innovation – JJDC, OrbiMed Israel Partners, Pontifax, and the Israel Innovation Authority, and has operated since March 2015 in the FutuRx biotech accelerator in Ness Ziona, Israel. The company’s mission is to develop novel first-in-class drugs directed against the ubiquitin-proteasome system (UPS), mainly for treatment of cancer.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

VBI Vaccines Inc. is a biopharmaceutical company focused on developing and commercializing vaccines for infectious diseases and immuno-oncology, operating in Israel, the United States, and internationally. The company’s flagship product, Sci-B-Vac, is a commercial-stage hepatitis B vaccine that effectively mimics all three viral surface antigens, providing rapid protection and high antibody levels with lower dosing requirements compared to traditional vaccines. VBI's innovative enveloped virus-like particle (eVLP) platform technology facilitates the creation of vaccines that closely resemble target viruses, enhancing immune responses. The company is advancing several clinical programs, including VBI-1901, an immunotherapeutic candidate for glioblastoma, and VBI-1501, a prophylactic vaccine for cytomegalovirus. VBI collaborates with various organizations, including Brii Biosciences and GlaxoSmithKline, and partners with the National Research Council of Canada to develop a pan-coronavirus vaccine. Headquartered in Cambridge, Massachusetts, VBI Vaccines Inc. aims to address unmet medical needs through its innovative vaccine solutions.

CathWorks Ltd. is a medical technology company that specializes in enhancing percutaneous coronary intervention (PCI) therapy decisions through its advanced computational science platform. Founded in 2013 and headquartered in Kfar-Saba, Israel, with an additional office in the United States, the company has developed the CathWorks FFRangio, a non-invasive device that provides objective, multi-vessel physiologic measurements. This tool transforms coronary angiography from a subjective visual assessment into an objective decision-making framework based on fractional flow reserve (FFR) metrics. By utilizing sophisticated algorithms to process visual information, CathWorks aims to improve the efficiency of cath lab operations and support healthcare providers in making data-driven clinical decisions.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

Eloxx Pharmaceuticals based in Israel is a Pontifax portfolio company established in 2013 by Dr. Silvia Noiman, that serves as its Executive Chairman and Dr. Shmuel Tuvia. The company, is a biopharmaceutical company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations including: Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, Tay-Sachs Hurler syndrome and many others. Eloxx Pharmaceuticals approach and knowhow allows moving rapidly from target drugs discovery program to clinical drug candidates. Building a robust pipeline of molecules designed for an array of nonsense genetic diseases. Translation of mRNA to a protein is the event where the cellular machinery, i.e. ribosome, ultimately dictates the quantity and timing for each protein to be produced. Thus, molecules that induce ribosomal readthrough overcome the nonsense mutations and allow production of a full-length functional protein. These molecules hold great therapeutic potential for the treatment of many genetic diseases.

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company based in Jerusalem, Israel, specializing in the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company’s lead product candidates include EB612, an oral formulation of parathyroid hormone currently in Phase II clinical trials for hypoparathyroidism, and EB613, which is also in Phase II trials for osteoporosis and under development for non-union fractures. Entera Bio employs proprietary delivery technology that protects large molecules and peptides in the gastrointestinal tract, making oral drug administration straightforward and user-friendly. The company has established a research collaboration and license agreement with Amgen Inc. to discover clinical candidates targeting inflammatory diseases and other serious conditions. Founded in 2009, Entera Bio is supported by a management team with over 50 years of combined experience in drug development.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

EyeYon Medical is an Israeli start-up company that develops innovative medical devices for the treatment of corneal edema. EyeYon Medical was founded by Dr. Daphna Ofer, a senior ophthalmologist, Dr. Arie Marcovich, a senior cornea surgeon, and Nahum Ferera, an experienced business executive. The company operates within the Van Leer Technology Incubator.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

Nutrinia Ltd. is a neonatology company focused on developing pharmaceuticals for rare gastrointestinal conditions affecting infants. Established in 2003 and based in Ramat-Gan, Israel, the company is advancing clinical programs, including NTRA-2112, which aims to treat intestinal malabsorption in preterm infants by reducing enteral nutrition intolerance and improving growth metrics, as well as shortening hospital stays. Another significant product in development is NTRA-9620, designed for short bowel syndrome, which promotes bowel adaptation post-surgery and minimizes the need for parenteral nutrition. Nutrinia's offerings primarily consist of oral insulin formulations that facilitate gut adaptation and rehabilitation, thereby enhancing nutritional absorption in infants.

Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Isfiya, Israel, specializing in the development of a capsule-based system for colorectal cancer screening. The company's flagship product, C-Scan, employs low-dose X-rays to screen for polyps, masses, and colorectal cancers without the need for bowel preparation or invasive procedures. The C-Scan system comprises three components: the C-Scan Cap, an ingestible capsule that captures and transmits structural data; the C-Scan Track, a biocompatible device worn on the patient's back for tracking and data recording; and C-Scan View, software for processing and visualizing the collected clinical data. This innovative approach allows for the detection of clinically significant polyps with accuracy comparable to traditional colonoscopy while eliminating the need for retrieval of the capsule post-examination. Check-Cap aims to market its products in the United States, Europe, Israel, and Japan.

HeadSense Medical Ltd. is an early-stage company based in Netanya, Israel, focused on developing non-invasive diagnostic devices for brain health. Established in 2011, the company has created a validated and CE Mark approved intracranial pressure (ICP) monitor that is applicable in various medical fields, including neurosurgery, neurology, emergency medicine, and critical care. The device allows healthcare professionals to diagnose and monitor critical clinical parameters without the need for invasive procedures. In addition to its ICP monitor, HeadSense is actively working on expanding its product offerings to include diagnostic tools for cerebral vasospasm, concussion, and the quantification of traumatic brain injury severity, among others. The company operates in both the U.S. and Israel, aiming to enhance patient outcomes through innovative monitoring solutions.

V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

cCAM Biotherapeutics Ltd. is a clinical-stage company focused on the discovery and development of novel immunotherapies for cancer treatment. Founded in 2010 and based in Misgav, Israel, the company is advancing its lead candidate, CM-10, an immunomodulatory antibody designed to counteract the immunosuppressive effects of CEACAM1, a protein utilized by cancer cells. By inhibiting this protein, CM-10 aims to stimulate a cancer-specific immune response, targeting various malignancies such as melanoma, non-small-cell lung cancer, bladder cancer, gastric cancer, colorectal cancer, and ovarian cancer. cCAM Biotherapeutics is dedicated to developing innovative therapeutic solutions to improve outcomes for cancer patients.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

Applied Immune Technologies Ltd. engages in development of therapeutic molecules for cancer, viral, and autoimmune diseases. The company develops T-Cell Receptor-Like (TCRL) antibodies that are targeted to intracellular-derived peptides for various therapeutic and diagnostic applications. Its TCRL antibodies also have diagnostic applications in pathology; and vaccine design, validation, and monitoring, as well as in the analysis of antigen presentation in disease. The company was formerly known as BioMimic Pharma. The company was founded in 2006 and is based in Haifa, Israel.

ProtAb develops therapeutic agents that modulate cytokine regulation, tipping the balance toward anti-inflammatory signaling pathways in the treatment of autoimmune and inflammatory diseases. Its first product, Prozumab, is a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for the treatment of inflammatory bowel disease or IBD, ulcerative colitis or UC, and rheumatoid arthritis or RA. It operates as a subsidiary of Hadasit Bio-Holdings. HBL is a publicly traded subsidiary of Hadasit, the technology transfer company of the Hadassah University Hospital in Jerusalem in Israel.

Aposense Ltd. is a biopharmaceutical company based in Petah Tikva, Israel, focused on developing innovative diagnostic and therapeutic drugs. Established in 1996, Aposense specializes in utilizing its patented platform technology to target apoptosis, or programmed cell death, which enables real-time imaging of disease activity and the development of targeted therapies. The company innovates in gene therapy by creating transport molecules that facilitate the introduction of genetic material, particularly small interfering RNA (siRNA), through biological membranes. Aposense is also known for its molecular nano-motors, which are designed to harness electrical properties of membranes for drug delivery, including its development of ATT-11T, a conjugate aimed at treating solid tumors.

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.

CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also develops and commercializes tissue repair products for orthobiologics. The company's products are based on the rhCollagen that is produced with CollPlant’s proprietary plant-based genetic engineering technology. The rhCollagen BioInk is ideal for 3D bioprinting of tissues and organs, and the unique Vergenix line of rhCollagen products contains a soft tissue repair matrix for treating tendinopathy and a wound repair matrix to promote rapid optimal healing of acute and chronic wounds. CollPlant is headquartered in Rehovot, Israel.